State of the Art in Nuclear Medicine Dose Assessment

Marinelli, 1948, Dosage determination with radioactive isotopes II, practical considerations in therapy and protection, Am J Roent Radium Ther, 59, 260 Quimby, 1963 Loevinger, 1988 Stabin, 2003, Physical models and dose factors for use in internal dose assessment, Health Phys, 85, 294, 10.1097/00004032-200309000-00006 1991 Snyder, 1969, MIRD Pamphlet No 5 - Estimates of Absorbed Fractions for Monoenergetic Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom, J Nucl Med Suppl, 3, 5 1975 2003 Snyder, 1978 Snyder, 1975 Cristy, 1987 Stabin, 1996, MIRDOSE: The personal computer software for use in internal dose assessment in nuclear medicine, J Nucl Med, 37, 538 Stabin, 2005, OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine, J Nucl Med, 46, 1023 Stabin, 1995, Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy, ORNL Report ORNL/TM-12907 Segars, 2001, Development and Application of the New Dynamic NURBS-based Cardiac-Torso (NCAT) Phantom, PhD Dissertation, The University of North Carolina Spiers, 1969, Beta dosimetry in trabecular bone, 95 Eckerman, 2000, Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions, Health Phys, 78, 199, 10.1097/00004032-200002000-00009 Bouchet, 2000, S-Values for radionuclides localized within the skeleton, J Nucl Med, 41, 189 Stabin, 2002, Evolution and status of bone and marrow dose models, Cancer Biother Radiopharm, 17, 427, 10.1089/108497802760363213 Shah, 2005, A paired-image radiation transport model for skeletal dosimetry, J Nucl Med, 46, 344 Siegel, 1999, MIRD Pamphlet No 16—Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates, J Nucl Med, 40, 37S Ogawa, 1991, A practical method for position-dependent Compton-scatter correction in single emission CT, IEEE Trans Medimag, 10, 408, 10.1109/42.97591 King, 2003, An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies, Cancer Biother Radiopharm, 18, 181, 10.1089/108497803765036346 Autret, 2005, Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy, Cancer Biother Radiopharm, 20, 77, 10.1089/cbr.2005.20.77 Dewaraja, 2005, Accurate dosimetry in I-131 radionuclide therapy using patient- specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation, J Nucl Med, 46, 840 Kirschner, 1975, Radiation dosimetry of 131I-19-iodocholesterol: The pitfalls of using tissue concentration data, the author's reply, J Nucl Med, 16, 248 Sgouros, 2004, Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software, J Nucl Med, 45, 1366 1989 2000 Snyder, 1970 Hindorf, 2003, Change in tumor absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients, Clin Cancer Res, 9, 4003s Siegel, 2007, Mass-scaling of S Values for blood-based estimation of red marrow absorbed dose: The quest for an appropriate method, J Nucl Med, 48, 253 Traino, 2006, Dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction, Phys Med Biol, 51, 6449, 10.1088/0031-9155/51/24/011 Hartman Siantar, 2003, Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy, J Nucl Med, 44, 1322 Traino, 2007, Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry, Phys Med Biol, 52, 5231, 10.1088/0031-9155/52/17/009 Stabin MG, Stubbs JB, Toohey RE: Radiation Dose Estimates for Radiopharmaceuticals. NUREG/CR-6345, prepared for: US Nuclear Regulatory Commission, US Department of Energy, US Department of Health & Human Services, 81 pages, 1996 1983 Kolbert, 1997, Implementation and evaluation of patient-specific three-dimensional internal dosimetry, J Nucl Med, 38, 301 Dewaraja, 2005, Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation, J Nucl Med, 46, 840 Liu, 1999, A radionuclide therapy treatment planning and dose estimation system, J Nucl Med, 40, 1151 Guy, 2003, RMDP: A dedicated package for I-131 SPECT quantification, registration and patient-specific dosimetry, Cancer Biother Radiopharm, 18, 61, 10.1089/108497803321269331 Clairand, 1999, DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry, J Nucl Med, 40, 1517 Bielajew, 1987, PRESTA: The parameter reduced electron-step transport algorithm for electron monte carlo transport, Nucl Instrum Methods, B18, 165 Briesmeister JF (ed): “MCNP—A General Monte Carlo N-Particle Transport Code, Version 4C,” LA-13709-M, Los Alamos National Laboratory April 2000 Allison, 2006, Geant4 developments and applications, IEEE Trans Nucl Sci, 53, 270, 10.1109/TNS.2006.869826 Lehmann, 2005, Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system, Phys Med Biol, 50, 947, 10.1088/0031-9155/50/5/017 Sgouros, 2004, Larson patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software, J Nucl Med, 45, 1366 DeNardo, 1997, Imaging for improved prediction of myelotoxicity after radioimmunotherapy, Cancer, 80, 2558, 10.1002/(SICI)1097-0142(19971215)80:12+<2558::AID-CNCR31>3.0.CO;2-9 Siegel, 1989, Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy, Int J Rad Appl Instrum (B), 16, 553, 10.1016/0883-2897(89)90070-6 Siegel, 1990, Bone marrow dosimetry and toxicity for radioimmunotherapy, Antibody Immunoconj Radiopharmacol, 3, 213 Lim, 1997, Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources, J Nucl Med, 38 Breitz, 1998, Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monocolonal antibody, J Nucl Med, 39, 1746 Eary, 1997, Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non Hodgkin's lymphoma, Nucl Med Biol, 24, 635, 10.1016/S0969-8051(97)00098-X Behr, 1999, Hematological toxicity in the radioimmunotherapy of solid cancers with 131I-labeled anti-CEA NP-4 IgG1, Dependence on red marrow dosimetry and pretreatment.in sixth international radiopharmaceutical dosimetry symposium, Vol I, 113 Juweid, 1999, Prediction of hematologic toxicity after radioimmunotherapy with 131I-labeled anticarcinoembryoinic antigen monoclonal antibodies, J Nuc Med, 10, 1609 Wiseman, 2003, Radiation Dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials, J Nucl Med, 44, 465 Shen, 2002, Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy, J Nucl Med, 43, 1245 Siegel, 2003, Red marrow radiation dose adjustment using plasma FLT3-l cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients, J Nucl Med, 44, 67 Pauwels, 2005, Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs, J Nucl Med, 46, 92S Kobe, 2008, Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy?, Nuklearmedizin, 47, 13, 10.3413/nukmed-0087 Smith, 1967, Clinical trial of different doses of 131I in treatment of thyrotoxicosis, Br Med J, 1, 129, 10.1136/bmj.1.5533.129 Becker, 1971, The results of radioiodine treatment of hyperthyroidism, 603 Dale, 2005, The radiobiology of conventional radiotherapy and its application to radionuclide therapy, Cancer Biother Radiopharm, 20, 47, 10.1089/cbr.2005.20.47 Bodey, 2003, Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose, Cancer Biother Radiopharm, 18, 89, 10.1089/108497803321269368 Barone, 2005, Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship, J Nucl Med, 46, 99S Dale, 1985, The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy, Br J Radiol, 58, 515, 10.1259/0007-1285-58-690-515 Sachs, 1997, The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair, Int J Radiat Biol, 72, 351, 10.1080/095530097143149 Lea, 1942, The mechanism of the induction by radiation of chromosome abberations in Tradescantia, J Genet, 44, 216, 10.1007/BF02982830 Barendson, 1982, Dose fractionation, dose-rate and iso-effect relationships for normal tissue responses, Int J Radiat Oncol Biol Phys, 8, 1981, 10.1016/0360-3016(82)90459-X Fowler, 1989, The linear-quadratic formula and progress in fractionated radiotherapy, Br J Radiol, 62, 679, 10.1259/0007-1285-62-740-679 Malaroda, 2003, Multicellular dosimetry in voxel geometry for targeted radionuclide therapy, Cancer Biother Radiopharm, 18, 451, 10.1089/108497803322285215 O'Donoghue, 2000, Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry, J Nucl Med, 41, 538 Prideaux, 2007, Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging–based internal dosimetry, J Nucl Med, 48, 1008, 10.2967/jnumed.106.038000 Bodey, 2004, Application of the linear-quadratic model to combined modality radiotherapy, Int J Radiat Oncol Biol Phys, 59, 228, 10.1016/j.ijrobp.2003.12.031 Hall, 2003, The bystander effect, Health Phys, 85, 31, 10.1097/00004032-200307000-00008 Khan, 1998, Partial volume rat lung irradiation: An evaluation of early DNA damage, Int J Radiat Oncol Biol Phys, 40, 10.1016/S0360-3016(97)00736-0 Sgouros, 2007, MIRD continuing education: Bystander and low–dose-rate effects: Are these relevant to radionuclide therapy?, J Nucl Med, 48, 1683, 10.2967/jnumed.105.028183 Wessels, 2004, Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison, J Nucl Med, 45, 1725 Eschmann, 2002, Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET, Eur J Nucl Med Mol Imaging, 29, 760, 10.1007/s00259-002-0775-8 Canzi, 2006, Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients, Med Phys, 33, 2860, 10.1118/1.2210564 Carlier, 2006, Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic I-131 activity, Nucl Med Commun, 27, 559, 10.1097/00006231-200607000-00003 Smith, 1967, Clinical trial of different doses of 131I in the treatment of thyrotoxicosis, Br Med J, 1, 129, 10.1136/bmj.1.5533.129 Grosso, 2005, Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism, Cancer Biother Radiopharm, 20, 218, 10.1089/cbr.2005.20.218 Furhang, 1999, Thyroid cancer dosimetry using clearance fitting, J Nucl Med, 40, 131 Maxon, 1997, Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer, Thyroid, 7, 183, 10.1089/thy.1997.7.183 Reiners, 1998, Radioiodine therapy of thyroid cancer, Tumordiagnostik Therapie, 19, 70 Benua, 1962, The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer, Am J Roentgenol Radium Ther Nucl Med, 87, 171 Ott, 1992, Treatment Planning for I-131 metaiodobenzylguanidine radiotherapy of neural crest tumors using I-124 metaiodobenzylguanidine positron emission tomography, Br J Radiol, 65, 787, 10.1259/0007-1285-65-777-787 Sgouros, 2004, Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software, J Nucl Med, 45, 1366 Dorn, 2003, Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach, J Nucl Med, 44, 451 Hanscheid, 2006, Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal, J Nucl Med, 47, 648 Lassman, 2004, Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants, J Nucl Med, 45, 619 Sisson, 2006, The so-called stunning of thyroid tissue, J Nucl Med, 47, 1406 Woolfenden, 2006, Thyroid stunning revisited, J Nucl Med, 47, 1403 Oyen, 2007, Targeted therapy in nuclear medicine—current status and future prospects, Ann Oncol, 18, 1782, 10.1093/annonc/mdm111 Ron, 1998, Cancer mortality following treatment for adult hyperthyroidism, JAMA, 280, 347, 10.1001/jama.280.4.347 Hoefnagel, 1999, Nuclear medicine therapy of neuroblastoma, Q J Nucl Med, 43, 336 Matthay, 2001, Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG, J Nucl Med, 42, 1713 Gaze, 2005, Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma, Cancer Biotherapy Radiopharm, 20, 195, 10.1089/cbr.2005.20.195 Monsieurs, 2002, Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans, Eur J Nucl Med Mol Imaging, 29, 1581, 10.1007/s00259-002-0973-4 Flux, 2003, Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG, Cancer Biother Radiopharm, 18, 81, 10.1089/108497803321269359 Garber, 2007, Users fear that lymphoma drugs will disappear, J Natl Cancer Inst, 99, 498, 10.1093/jnci/djk155 Wiseman, 2001, Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin's lymphoma, Crit Rev Oncol Hematol, 39, 181, 10.1016/S1040-8428(01)00107-X Wahl, 1998, Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation, J Nucl Med, 39, 14S Cremonesi, 2000, Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience, Q J Nucl Med, 44, 325 Hindorf, 2007, Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors, Cancer Biother Radiopharm, 22, 130, 10.1089/cbr.2007.306 Barone, 2002, Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy, J Nucl Med, 43, 1267 Esser, 2006, TI Comparison of [Lu-177-DOTA(0), Tyr(3)] octreotate and [Lu-177- DOTA(0), Tyr(3)] octreotide: Which peptide is preferable for PRRT?, Eur J Nucl Med Mol Imaging, 33, 1346, 10.1007/s00259-006-0172-9 Gotthardt, 2007, Indication for different mechanisms of kidney uptake of radiolabeled peptides, J Nucl Med, 48, 596, 10.2967/jnumed.106.036020 EURATOM: Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council directive 97/43 EURATOM, 1997 Parthasarathy, 2002, Treatment of thyroid carcinoma: Emphasis on high-dose 131I outpatient therapy, J Nucl Med Technol, 30, 165 Solans, 2001, Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy, J Nucl Med, 42, 738 Siegel, 2002, The importance of patient-specific radiation dose calculations for the administration of radionuclides in therapy, Cell Mol Biol, 48, 451 Thierens, 2005, Patient dosimetry in radionuclide therapy: The whys and the wherefores, Nucl Med Commun, 26, 593, 10.1097/01.mnm.0000167910.76718.ad Robbins, 2005, The evolving role of 131I for the treatment of differentiated thyroid carcinoma, J Nucl Med, 46, 28S